She sat on Enthera's board and chaired its science committee. When the company needed a chief executive, it looked across the table - and handed her the keys.
// The board member who knew the molecules best. Now the one accountable for them.
Ent001 is a monoclonal antibody aimed at a pathway most people have never heard of - IGFBP3 binding to a receptor called TMEM219. It is the kind of biology that lives in dense journal figures and gets explained at conferences in twelve-minute talks. Lisa Olson's job is to turn it into a medicine. In January 2024 she became Chief Executive Officer of Enthera Pharmaceuticals, the clinical-stage biotech building its future on that single axis.
The timing was deliberate. Her appointment landed alongside results: a completed Phase 1a study in 30 healthy volunteers that reported no drug-related adverse reactions up to a 10 mg/kg dose, and a freshly launched Phase 1b in patients with moderately-to-severely active ulcerative colitis. A CEO announcement is usually a press release. Hers came stapled to data.
She was not a stranger walking into the building. Olson had already served on Enthera's Board of Directors and chaired its Scientific Advisory Board - she helped vet the science before she was asked to run the business behind it. Few CEOs arrive knowing the lead asset down to its receptor.
Enthera itself is an Italian company, headquartered on Via Borgogna in central Milan, with an American immunologist at the helm and a pipeline pointed at two diseases that rarely share a stage: inflammatory bowel disease and type 1 diabetes. The connective tissue between them is the biology Olson spent her career learning to read.
My goal is to ensure we deliver on the potential of Ent001 in the clinic and to achieve our ambitious corporate objectives for 2024.— Lisa M. Olson, on becoming CEO of Enthera Pharmaceuticals
The career did not start in a boardroom. It started at a chalkboard. Olson's first title was Assistant Professor at Washington University School of Medicine, following a post-doctoral cardiovascular fellowship at the University of Chicago. Before that came a Ph.D. from the University of Illinois at Urbana-Champaign and a B.S. from Iowa State University - a Midwestern academic spine that runs underneath everything she has built since.
Industry came calling through Pfizer, where she worked as a Research Fellow in Inflammation and Immunology. Then came the fifteen-year run that defines her resume: AbbVie and, before the split, Abbott Laboratories. She climbed to Vice President of Immunology Discovery and Site Head of the AbbVie Bioresearch Center, the kind of role where the spreadsheets describe pipelines and the meetings decide which programs live.
It was there she helped advance 15 molecules into clinical development - among them Rinvoq (upadacitinib), now one of the most recognizable names in immunology. Few scientists get to point at a pharmacy shelf and say they were in the room. Olson can.
Before Enthera, she was Chief Scientific Officer at Magenta Therapeutics, running R&D strategy. Each move traded a little more lab time for a little more decision-making, until the natural endpoint arrived: not the person who designs the science, but the person accountable for whether it reaches patients.
Ent001 is built around a deceptively simple idea: block the wrong signal, and cells that were dying in the gut and the pancreas might be coaxed back to function. It is a monoclonal antibody targeting the IGFBP3/TMEM219 axis - the molecular thread Enthera believes connects inflammatory bowel disease and type 1 diabetes.
Ent001's antibody intercepts that signal. Phase 1a in 30 healthy volunteers reported a clean safety and tolerability profile with no drug-related adverse reactions up to 10 mg/kg. Phase 1b is now running in up to 40 patients with active ulcerative colitis - the first real test of whether the biology behaves in people the way it did on the page.
Most CEOs spend their first months learning the lead asset. Olson chaired the Scientific Advisory Board that helped validate it. Her promotion was an elevation, not an orientation.
Among the 15 molecules she helped move into the clinic at AbbVie was Rinvoq - upadacitinib - now a household name in immunology circles. Few scientists can say that.
An American immunologist trained across the US Midwest, now leading an Italian biotech headquartered on Via Borgogna in the center of Milan. The pipeline doesn't care about passports.
Enthera draws money from a rare coalition: Sofinnova Partners, AbbVie, the JDRF T1D Fund, the Roche Venture Fund, and private investors - venture capital and pharma sitting side by side.
Assistant professor, research fellow, VP, CSO, CEO. Each step traded a little bench time for a little more accountability. The endpoint: the person who answers for the whole thing.
Her CEO announcement arrived the same day as Ent001's Phase 1a results and Phase 1b launch. A leadership change packaged as a progress report.
I look forward to working with the Enthera team to further drive Ent001's clinical development trajectory.
My goal is to ensure we deliver on the potential of Ent001 in the clinic and to achieve our ambitious corporate objectives for 2024.
She is an American executive running an Italian biotech - the company files in Milan, the CEO thinks in Boston.
Her career touches four of immunology's biggest names: Pfizer, AbbVie, Magenta, and now Enthera.
The IGFBP3/TMEM219 pathway was a niche piece of biology. She championed it first as a science advisor, then as the boss.
Her academic roots are pure Midwest: a B.S. from Iowa State and a Ph.D. from the University of Illinois at Urbana-Champaign.